Danske Bank’s Insight Molecular Diagnostics IMDX Stock Holding History

Danske Bank’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$2	–	1432
2024 Q4	$2	Hold	1	–	–	﹤0.01%	1384
2024 Q3	$3	Buy	+1	New	+$3	﹤0.01%	1564

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIA

Wealthedge Investment Advisors New York $294M AUM 20.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Danske Bank's IMDX Position: Q1 2025 in Review

Danske Bank sold out of Insight Molecular Diagnostics (IMDX) in Q1 2025, closing a stake of 1 share — an estimated $2 sold.

Danske Bank first reported a position in IMDX in Q3 2024 and held it in 2 quarters. The position peaked at $3 in Q3 2024. 30 funds tracked by Wall St. Rank hold IMDX as of Q1 2025.

Danske Bank reported no remaining Insight Molecular Diagnostics position as of Q1 2025 after selling out during the quarter.
Danske Bank sold 1 Insight Molecular Diagnostics share in Q1 2025, an estimated $2.
Danske Bank first reported a position in Insight Molecular Diagnostics in Q3 2024 and held it in 2 quarters.
Danske Bank's Insight Molecular Diagnostics position peaked at $3 in Q3 2024.
30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2025.

Based on Danske Bank's 13F filing for Q1 2025, filed 18 Dec 2025.